{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"82"}],"units":"Participants"}],"groups":[{"description":"lenalidomide 15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone 20 mg daily (10 mg twice daily) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.\n\ndexamethasone: dexamethasone 20 mg daily (10 mg twice daily) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.\n\nlenalidomide: 15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone","id":"OG000","title":"Revlimid"}],"paramType":"NUMBER","populationDescription":"Number of patients who had at least one dose of CC-5013","reportingStatus":"POSTED","timeFrame":"1 year","title":"Number of Patients Removed From Study Treatment Due to Toxicities","type":"PRIMARY","unitOfMeasure":"participants"}